Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women
Authors
Evans, D Gareth RHowell, Sacha J
Gandhi, Ashu
van Veen, E. M.
Woodward, E. R.
Harvey, J.
Barr, L.
Wallace, A.
Lalloo, F.
Wilson, M.
Hurley, E.
Lim, Y.
Maxwell, A. J.
Harkness, E. F
Howell, Anthony
Affiliation
Clinical Genetics Service, Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, M13 9WL, UK.Issue Date
2021
Metadata
Show full item recordAbstract
Purpose: Women at increased familial breast cancer risk have been offered screening starting at an earlier age and increased frequency than national Screening Programmes for over 30 years. There are limited data on longer-term largescale implementation of this approach on cancer diagnosis. Methods: Women at our institution at ≥ 17% lifetime breast cancer risk have been offered enhanced screening with annual mammography starting at age 35 or 5-years younger than youngest affected relative, with upper age limit 50 for moderate and 60 for high-risk. Breast cancer pathology, stage and receptor status were assessed as well as survival from cancer diagnosis by Kaplan-Meier analysis. Results: Overall 14,311 women were seen and assessed for breast cancer risk, with 649 breast cancers occurring in 129,119 years follow up (post-prevalent annual incidence = 4.55/1000). Of 323/394 invasive breast cancers occurring whilst on enhanced screening, most were lymph-node negative (72.9%), T1 (≤ 20 mm, 73.2%) and stage-1 (61.4%), 126/394 stage2-4 (32%). 10-year breast cancer specific survival was 91.3% (95% CI 87.4-94.0) better than the 75.9% (95% CI 74.9-77.0) published for England in 2013-2017. As expected, survival was significantly better for women with screen detected cancers (p < 0.001). Ten-year survival was particularly good for those diagnosed ≤ 40 at 93.8% (n = 75; 95% CI 84.2-97.6). Women with lobular breast cancers had worse 10-year survival at 85.9% (95% CI 66.7-94.5). Breast cancer specific survival was good for 119 BRCA1/2 carriers with 20-year survival in BRCA1:91.2% (95% CI 77.8-96.6) and 83.8% (62.6-93.5) for BRCA2. Conclusions: Targeted breast screening in women aged 30-60 years at increased familial risk is associated with good long-term survival that is substantially better than expected from population data.Citation
Evans DG, Howell SJ, Gandhi A, van Veen EM, Woodward ER, Harvey J, et al. Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women. Breast Cancer Res Treat. 2021 Jul 26.Journal
Breast Cancer Research and TreatmentDOI
10.1007/s10549-021-06333-1PubMed ID
34312777Additional Links
https://dx.doi.org/10.1007/s10549-021-06333-1Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1007/s10549-021-06333-1
Scopus Count
Collections
Related articles
- Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
- Authors: Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, Hoogerbrugge N, Oosterwijk JC, Tollenaar RA, Hooning M, Loo CE, Obdeijn IM, Heijnsdijk EA, de Koning HJ
- Issue date: 2013 Sep 4
- Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
- Authors: Saadatmand S, Vos JR, Hooning MJ, Oosterwijk JC, Koppert LB, de Bock GH, Ausems MG, van Asperen CJ, Aalfs CM, Gómez Garcia EB, Meijers-Heijboer H, Hoogerbrugge N, Piek M, Seynaeve C, Verhoef C, Rookus M, Tilanus-Linthorst MM, Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)
- Issue date: 2014 Dec 15
- Earlier detection of breast cancer by surveillance of women at familial risk.
- Authors: Tilanus-Linthorst MM, Bartels CC, Obdeijn AI, Oudkerk M
- Issue date: 2000 Mar
- Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
- Authors: Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM
- Issue date: 2006 May 24
- Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
- Authors: Fakkert IE, Jansen L, Meijer K, Kok T, Oosterwijk JC, Mourits MJ, de Bock GH
- Issue date: 2011 Aug